Mazyar Shadman, MD, MPH
Enriched profileDeputy Chief Medical Officer, Fred Hutchinson Cancer Research Center; Professor, Clinical Research Division; Medical Director, Cellular Immunotherapy and Bezos Family Immunotherapy Clinic · Fred Hutchinson Cancer Research Center
Mazyar Shadman is Deputy Chief Medical Officer, Fred Hutchinson Cancer Research Center; Professor, Clinical Research Division; Medical Director, Cellular Immunotherapy and Bezos Family Immunotherapy Clinic at Fred Hutchinson Cancer Research Center. OpenAlex indexes 658 publications with 9,421 citations (h-index 48); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 23 Oct 2026
Mazyar Shadman, MD,MPH, is Deputy Chief Medical Officer, Fred Hutchinson Cancer Research Center. The public record shows 658 publications with 9,421 citations (h-index 48), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 33 companies.
- Most recent indexed publication: 2026 · Journal of medical economics
- Top research focus: Lymphoma Diagnosis and Treatment
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 33 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 76 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 166.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
Sponsor: SWOG Cancer Research Network
- Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor: Fred Hutchinson Cancer Center
Industry payments
Updated 23 Oct 2026
33 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202513 payments
- E.R. Squibb & Sons, L.L.C.Program year20254 payments
- Genentech USA, Inc.Program year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Brukinsa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 23 Oct 2026
199 congress contributions (2012–2026) across ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Phase 2 trial of lisocabtagene maraleucel for minimal residual disease in patients with large B-cell lymphoma.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.
Journal of clinical oncology
Article2026 - Association between patient-reported symptoms and clinical outcomes in R/R CLL.
Blood advances
Article2026
Most-cited works
by citation count (OpenAlex)- 01Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaArticle491 citations2022
- 02
- 03
- 04
- 05Outcomes of COVID-19 in patients with CLL: a multicenter international experienceArticle305 citations2020
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/mazyar-shadman-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fredhutch.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- MD
Tehran University of Medical Sciences
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - MPH in Cancer Epidemiology
University of Washington School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Editorial & leadership roles
journal and society appointments- Member
NCCN Guidelines Committee for Chronic Lymphocytic Leukemia and Hairy Cell Leukemia
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nccn.digitellinc.com ↗
Awards & honors
honors on the public record- Harr Family Endowed Chair in Immunotherapy
Fred Hutchinson Cancer Research Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Secondary affiliations
appointments beyond the home institution- Professor
Division of Hematology and Oncology, University of Washington School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - Member
Immunotherapy Integrated Research Center (IIRC), Fred Hutchinson Cancer Research Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Mohamed Sorror, MD
Fred Hutchinson Cancer Research Center
Bart Scott, MD
Fred Hutchinson Cancer Research Center
Joshua Schiffer, MD
Fred Hutchinson Cancer Research Center
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Thomas Witzig, MD
Mayo Clinic
Wyndham Wilson, MD
National Cancer Institute (NCI)